Sodium nitroprusside Clinical Trials

Size	Price	Qty
100mg	USD 147
1g	USD 497

Clinical Trials

Numerous clinical trials evaluate sodium nitroprusside across all developmental phases, from Early Phase 1 to Phase 4, for a range of cardiovascular, respiratory, oncological, and physiological conditions such as hypertension, acute respiratory distress syndrome, non-small cell lung cancer, and sarcopenia. Sponsored by academic medical centers, government agencies, and pharmaceutical companies, these studies represent various recruitment statuses including completed, actively recruiting, terminated, and not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01199250	Not yet recruiting	Lynch Syndrome\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	2100-01	--
NCT06424756	RECRUITING	Healthy	University of Georgia	2024-07-01	PHASE2
NCT02560805	RECRUITING	Stress Disorders, Post-Traumatic	Emory University	2015-10	PHASE2
NCT05193968	RECRUITING	Hot Flashes; Menopause; Vasomotor System; Labile	Mayo Clinic	2022-02-24
NCT03318094	ACTIVE_NOT_RECRUITING	Insulin Resistance; Healthy; Obesity	Vanderbilt University Medical Center	2017-10-24	PHASE1
NCT02966665	RECRUITING	Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension	Russell Richardson	2008-09	PHASE1
NCT04986072	TERMINATED	Schizophrenia; Schizoaffective Disorder	Beth Israel Deaconess Medical Center	2022-03-14	PHASE2
NCT06405945	Recruiting	Cervical Cancer Susceptible Population Classification	Anhui Provincial Hospital	2024-05-01	--
NCT05987956	Not yet recruiting	Non-small Cell Lung Cancer	Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair\|Medicine Invention Design Inc	2024-03-08	Phase 2\|Phase 3
NCT06062810	Not yet recruiting	Non-Small Cell Lung Cancer	Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair\|Medicine Invention Design Inc	2024-03-28	Phase 2\|Phase 3
NCT06265623	Not yet recruiting	Chronic Obstructive Pulmonary Disease (COPD)	Universitätsklinikum Hamburg-Eppendorf	2024-03-01	--
NCT03679780	COMPLETED	Cardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction	The University of Texas at Arlington	2018-10-01	PHASE1
NCT05525416	COMPLETED	Vasodilation; Vasoconstriction	University of Alberta	2022-07-28
NCT04001647	TERMINATED	Vasodilation; Arterial Stiffness	Colorado State University	2019-06-01	EARLY_PHASE1
NCT05277922	COMPLETED	Study Vasodilatory Effects of C21	Vicore Pharma AB	2022-04-28	PHASE1
NCT04928183	COMPLETED	Vasodilation; Vasoconstriction	University of Alberta	2021-06-10
NCT03972683	WITHDRAWN	Vasoconstriction; Vasodilation	Colorado State University	2019-04-16	EARLY_PHASE1
NCT03738943	COMPLETED	Receptor Blockade	Colorado State University	2019-02-07	EARLY_PHASE1
NCT03953326	TERMINATED	Breast Cancer; Leukemia; Lymphoma	Penn State University	2019-04-23	PHASE1; PHASE2
NCT03446612	TERMINATED	Anaemia	GlaxoSmithKline	2019-01-10	PHASE2
NCT03680573	COMPLETED	Cardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction	The University of Texas at Arlington	2018-01-08	PHASE1
NCT02767024	WITHDRAWN	Acute Heart Failure	Montefiore Medical Center	2018-05-01	PHASE4
NCT03317652	COMPLETED	Healthy Male Subjects	Rigshospitalet, Denmark	2017-11-03
NCT02164981	COMPLETED	Schizophrenia	Massachusetts General Hospital	2015-05-01	PHASE2
NCT00580905	TERMINATED	Inflammation	Vanderbilt University	2007-06	PHASE1
NCT01395329	COMPLETED	Prehypertension; Hypertension	University of Colorado, Boulder	2011-05	PHASE4
NCT02176044	COMPLETED	Schizophrenia	King's College London	2014-08	PHASE1
NCT00891696	COMPLETED	Sarcopenia	The University of Texas Medical Branch, Galveston	2009-04	PHASE1
NCT01747174	COMPLETED	ST-elevation Myocardial Infarction (STEMI)	University Hospitals, Leicester	2011-10	PHASE2
NCT01619280	UNKNOWN	Acute Lung Injury; Acute Respiratory Distress Syndrome; Sodium Nitroprusside; Hypoxia; Respiratory Failure	Mount Sinai Hospital, Canada	2012-05	PHASE1
NCT00166166	TERMINATED	Hyperlipidemia	Emory University	2002-07	PHASE2
NCT01333891	TERMINATED	Healthy	Medical University of Vienna	2012-12
NCT00690534	COMPLETED	Sarcopenia	The University of Texas Medical Branch, Galveston	2005-09	PHASE1
NCT00621816	COMPLETED	Hypertension	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2009-01	PHASE2
NCT00901719	COMPLETED	Heart Disease; Heart Failure; Vasodilatation	University of Edinburgh	2010-04
NCT00901888	COMPLETED	Heart Disease; Vasodilation	University of Edinburgh	2009-04
NCT02085317	COMPLETED	Lepromatous Leprosy	Curt Treu	2006-03
NCT01548612	COMPLETED	Schizophrenia	University of Sao Paulo	2006-02	PHASE2
NCT00945256	COMPLETED	Aging	The University of Texas Medical Branch, Galveston	2003-05	PHASE1
NCT00135668	COMPLETED	Hypotension	The Emmes Company, LLC	2005-08	PHASE2
NCT00636584	UNKNOWN	Nitroprusside; Thyroid Hormones	Kavaklıdere Umut Hospital	2008-02	PHASE4
NCT00093912	COMPLETED	Hypertension	The Medicines Company	2004-06	PHASE3
NCT00810381	COMPLETED	Glaucoma	Medical University of Vienna	1999-01
NCT00253929	COMPLETED	Blood Flow in Healthy Volunteers	Radboud University Medical Center	2005-11
NCT00160888	UNKNOWN	Healthy	Heidelberg University	1999-11	PHASE1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Sodium nitroprusside product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Sodium nitroprusside acts as a nitric oxide donor that activates soluble guanylyl cyclase in vascular smooth muscle cells, driving the intracellular accumulation of cyclic guanosine monophosphate and activation of downstream protein kinase G signaling. This physiological cascade induces potent vascular smooth muscle relaxation and systemic vasodilation, effectively reducing peripheral vascular resistance to manage hypertensive crises and improve pulmonary hemodynamics in patients with acute lung injury and respiratory failure.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).